Stockwinners Market Radar for November 18, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:29 EST Myovant Sciences up over 11% after announcing Phase 3 Study conference call - Shares of Myovant Sciences are up 11.7% or 71c at $6.77 in the afterhours session. After the close, the company announced that it will hold a conference call at 8:30am ET on Tuesday, November 19, 2019, to discuss results from the Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer.

18:38 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: America's Car-Mart (CRMT) up 9.5%... 58.com (WUBA) up 3.8%... Bilibili (BILI) up 3.7%. ALSO HIGHER: SAExploration Holdings (SAEX) up 168.4% after getting $130M in new projects... Clovis Oncology (CLVS) up 5.8% after DE Shaw reported passive 5.4% stake... ServiceNow (NOW) Up 3.6% after announced entry into S&P500 index... Okta (OKTA) up 2.2% after being upgraded to Buy at DA Davidson... Splunk (SPLK) up 1.0% after being initiated at Buy at DA Davidson. DOWN AFTER EARNINGS: Woodward (WWD) down 5.4%... Kornit Digital (KRNT) down 4.9%... Ashland Global (ASH) down 3.4%... 21Vianet (VNET) down 2.8%. ALSO LOWER: DHT Holdings (DHT) down 5.6% after equity offering... Karuna Therapeutics (KRTX) down 4.2% after equity offering... 8x8 (EGHT) down 3.9% after convertible debt offering... Intelsat (I) down 3.7% after being downgraded to In Line at Evercore... Performance Food Group (PFGC) down 3.2% after equity offering... Ellington Financial (EFC) down 2.5% after equity offering. Movers as of 18:30ET.

18:09 EST AbbVie treatment of myelofibrosis granted FDA orphan status - AbbVie's navitoclax was granted FDA orphan designation in the treatment of myelofibrosis, according to a post to the agency's website.Reference Link

18:03 EST Bilibili reports average MAUs reached 127.9M in Q3 - Average monthly active users reached 127.9M, mobile MAUs reached 114.2M, representing increases of 38% and 43% from the same period in 2018, respectively. Average daily active users reached 37.6M, a 40% increase from the same period in 2018. Revenue per MAU was RMB14.5, a 25% increase from the same period in 2018. Non-game revenue per MAU was RMB7.2, a 100% increase from the same period in 2018. Average monthly paying users reached 7.9M, a 124% increase from the same period in 2018. Average monthly paying users for mobile games increased to approximately 1.5M, compared to 0.9M for the same period in 2018.

17:54 EST Granite Construction awarded $14M airfield improvement project in California - Granite announced it was awarded task orders totaling $14M by Naval Facilities Engineering Command, Southwest, San Diego, California under a multiple award construction contract to repair taxiway India at Naval Base Coronado. To replace existing deteriorated concrete with new compliant airfield pavement, Granite's scope of work includes reconstruction of taxiway, demolition, earthwork, and construction of base, pavement, shoulders, striping, associated electrical along with incidental related work, cement stabilization, and replacement of waterline. Work will be performed in San Diego, California, and is expected to be completed by December 2020.

17:39 EST BAE Systems awarded $104.78M Navy contract for engineering, technical services - BAE Systems was awarded a $104.78M cost-plus-fixed-fee, cost reimbursable, indefinite-delivery/indefinite-quantity contract. This contract will provide engineering and technical services to support production, lifetime support engineering and in-service engineering for the radio communication system/command, control, communications, computers, combat systems, intelligence, surveillance, and reconnaissance systems aboard Navy surface combatants and at associated shore sites. The shipboard efforts are focused primarily on Coast Guard 47 Class and Destroyer, Guided Missile 51 Class AEGIS ships but will be applied to all Navy ships, to include Coast Guard ships, subsurface vessels and non-combatants in support of the Ship and Air Integration Warfare Division, Naval Air Warfare Center Webster Outlying Field. Work is expected to be completed in April 2025. No funds will be obligated at the time of award. Funds will be obligated on individual orders as they are issued. This contract was competitively procured via an electronic request for proposal; one offer was received. The Naval Air Warfare Center is the contracting activity.

17:32 EST Quarterhill'S WI-Lan settles patent litigation with Rogers - Wi-LAN, a Quarterhill (QTRH) company, announced that it has settled its Canadian patent litigation with Rogers (RCI) and Bell. The terms of the settlement, including any consideration agreed upon, are confidential.

17:27 EST Paulson & Co. lowers stake in Callon Petroleum to 4.5% from 9.5%

17:18 EST ServiceNow to replace Celgene in S&P 500 at open on 11/21 - Bristol-Myers Squibb (BMY) is acquiring Celgene (CELG) in a deal expected to be completed soon pending final conditions

17:05 EST Ashland down 6.5% to $73.50 after preliminary Q4 results miss estimates

17:03 EST ConnectOne Bancorp receives regulatory approvals for Bancorp of NJ deal - ConnectOne Bancorp announced that its wholly-owned bank subsidiary, ConnectOne Bank, has received regulatory approvals to proceed with its previously announced acquisition of Bank of New Jersey, a New Jersey state-chartered bank and wholly-owned bank subsidiary of Bancorp of New Jersey, Inc. Approval was granted by both the New Jersey Department of Banking and Insurance and the Federal Deposit Insurance Corporation. Additionally, the company announced that it has previously obtained from the Board of Governors of the Federal Reserve System a waiver from the application requirements of Section 3 of the Bank Holding Company Act of 1956, as amended, with respect to the merger of Bancorp of New Jersey, Inc. with and into the company. The proposed transaction, which is expected to close early in the first quarter of 2020, remains subject to the approval of the company's and Bancorp of New Jersey, Inc.'s shareholders and other customary closing conditions. ConnectOne and Bancorp of New Jersey, Inc. will hold their respective shareholder meetings on December 9, 2019 to vote on the proposed acquisition.

17:01 EST Civeo names Carolyn Stone as new CFO - Civeo announced that Carolyn Stone, currently the company's Chief Accounting Officer, has been appointed to the position of CFO and Treasurer of Civeo, effective immediately. Frank C. Steininger will remain with Civeo until his retirement in March 2020 and will focus on the company's strategic initiatives, as well as facilitating Ms. Stone's transition into her new role.

16:48 EST GCP Applied Technologies files patent infringement suit against AVM Industries - GCP Applied Technologies announced that it has filed a patent infringement lawsuit against AVM Industries in the United States District Court for the Central District of California. In the complaint, GCP alleges that AVM's unauthorized use and sale of waterproofing membranes such as Aussie Skin 550 and Aussie Skin 560, which are imported from China, has infringed and continues to infringe GCP's U.S. Patent No. 8,713,879, entitled "Waterproofing Membrane." The lawsuit seeks injunctive relief against further infringement, as well as damages and attorney's fees in amounts to be determined at trial. GCP has marketed and sold PREPRUFE pre-applied waterproofing membranes for years and has constantly evolved and improved its waterproofing membrane technology through continuing investments in research and development, innovation and intellectual property, which it intends to protect vigorously. The technology described in the aforementioned patent is based on and employs PREPRUFE technology, which enhances the bonding of concrete to the adhesive and minimizes waste paper at the jobsite. GCP owns an array of patents domestically and internationally covering its various waterproofing membrane technologies.

16:41 EST Corporacion America Airport reports October passenger traffic flat y/y - Corporacion America Airport reported preliminary unchanged year-over-year passenger traffic in October 2019. Total passenger traffic in October 2019 remained flat YoY, with traffic unchanged in Argentina, increases of 12.6% in Armenia and 1.8% in Italy, partially offset by declines in Brazil, Ecuador and Uruguay. Cargo volume declined 6.0% YoY in October 2019, mainly as a result of declines of 11.5% in Argentina and 25.3% in Ecuador, partially offset by an increase of 17.8% in Brazil. Aircraft movements declined 5.1% YoY in October 2019, mainly as a result of declines of 7.6% in Argentina, 8.7% in Brazil and 19.5% in Uruguay, partially offset by increases of 22.8% in Armenia and 6.0% in Ecuador.

16:38 EST Genuine Parts elects William Stengel chief transformation officer - Genuine Parts (GPC) announced that its board has elected William Stengel to the position of executive VP and chief transformation officer. In this leadership role, Stengel has responsibility for the effective management of GPC's short- and long-term transformation including strategic growth, operating efficiency and cost saving initiatives across the organization. Stengel joins Genuine Parts after spending more than a decade serving in various leadership roles at HD Supply (HDS). Most recently, Stengel served as president and CEO of HD Supply Facilities Maintenance.

16:33 EST Geospace receives $12.5M order from SAExploration - Geospace Technologies (GEOS) announced the receipt of an order for its GCL wireless recording system from SAExploration, a wholly-owned subsidiary of SAExploration Holdings,(SAEX). The order is for 30,000 single-channel recording stations and related equipment. Revenue on the order will be approximately $12.5 million and the company expects delivery of the system to occur in its second quarter ending March 31, 2020. Walter Wheeler, President and CEO of Geospace Technologies, said, "Our GCL represents the most advanced technology available in cable-free seismic recording systems, and we are very appreciative of the conscious choice made by SAExploration to incorporate this unique technology in their operations."

16:28 EST Assured Guaranty CIO acquires roughly 25,000 common shares - In a regulatory filing, Assured Guaranty chief investment officer Andrew T. Feldstein disclosed the acquisition of 25,22 common shares of the company in two transactions of 12,611 shares each. The first transaction was bought at $48.34 per share on November 14 while the second transaction was bought at $48.40 per share on November 15.

16:23 EST Esco Technologies divests technical packaging business segment to Sonoco - Esco Technologies (ESE) announced it has entered into a definitive agreement regarding the sale of its technical packaging business segment, consisting of Thermoform Engineered Quality, Plastique and Plastique sp. z o.o. to Sonoco Plastics and Sonoco (SON). The company expects to finalize the transaction upon receipt of certain customary regulatory approvals with expected gross cash proceeds of $187M subject to typical post-closing adjustments. The divestiture is part of the company's strategy to focus on the business units which are core to its long-term growth, and represents an important step in advancing this growth strategy by monetizing the technical packaging segment at an opportunistic valuation.

16:19 EST SAExploration announces $130M in new projects in Alaska, Canada and Middle East - SAExploration Holdings announced a combined $130M of new projects in Alaska, Canada and the Middle East. The largest contract is valued at approximately $112Mn for onshore data acquisition services to be performed on the North Slope of Alaska. The data acquisition services will be conducted over the next three winter seasons, beginning in Q1 2020. In association with this multi-year project award, SAE has entered into a separate agreement with Geospace Technologies Corporation to purchase 30,000 new state-of-the-art GCL recording channels. The new Geospace channels will primarily be utilized during the aforementioned multi-year contract in Alaska, but are also intended to be utilized in other regions, when available, during the off season. The balance of the new project awards consists of various contracts in Canada, slated to be performed primarily during the upcoming Q1 2020 winter season, and a new research and development pilot contract in the Middle East with two major integrated oil companies, where thousands of next-generation wireless sensors, dropped by a smart, automated fleet of drones, will take high-density, 3D images of the subsurface. Michael Faust, Chairman and CEO of SAE, commented "We are very pleased to announce these new projects and are grateful that our customers have displayed such confidence in our ability to continue to deliver high quality products and services safely and efficiently. Our backlog for the remainder of 2019 is approximately $67 million and our contracted backlog for 2020 is already at approximately $96 million. SAE is committed to deploying cutting edge technology to further minimize our footprint and reduce environmental exposure everywhere we operate. The purchase of 30,000 small light-weight GCL recording channels, and the automated drone deployment pilots, are strong examples of that commitment to continuously raising the bar on health, safety and environmental protection."

16:17 EST Zillow president of media and marketplaces, Greg Schwartz, steps down - Zillow announced that Greg Schwartz, president of media and marketplaces, is stepping down to take a professional break. The businesses that currently report to Schwartz in the Mortgages and Internet, Media and Technology segments are being transitioned to other senior executives to further align key company operations to deliver a seamless, Zillow-branded, real estate transaction experience.

16:16 EST Sonoco to acquire TEQ from Esco Technologies for $187M, sees deal as accretive - Sonoco (SON) announced it has signed a definitive agreement to acquire Thermoform Engineered Quality, and Plastique Holdings, together TEQ, "a global manufacturer of thermoformed packaging serving healthcare, medical device and consumer markets, from ESCO Technologies (ESE) for approximately $187M in cash. TEQ, headquartered in Huntley, Ill., produced sales of $88 million in the fiscal year ended September 30, 2018, and operates three thermoforming and extrusion facilities in the United States along with a thermoforming operation in the United Kingdom, and thermoforming and molded-fiber manufacturing in Poland. Each facility has state-of-the-art cleanroom capabilities, enabling the production of sterile, barrier packaging systems for pharmaceuticals and medical devices. In addition, TEQ produces recyclable, molded-pulp-fiber packaging and thermoformed plastic packaging for multiple consumer products primarily in Europe. The company has approximately 500 associates. "Recent studies value the global healthcare packaging market at approximately $33 billion, with healthy growth expected for the future," said Rob Tiede, Sonoco President and CEO. "Increased life expectancy, the steady introduction of new products from medical device manufacturers and pharmaceutical companies, combined with requirements for improved safety and compliance, are driving market growth." The transaction is expected to be accretive to Sonoco's 2020 earnings, and TEQ's financial results will be reported within Sonoco's Consumer Packaging segment.

16:13 EST Euroseas to acquire four containerships from Synergy Holdings for $40M - Euroseas announced that it has entered into agreements to acquire four 4,253 teu containerships built in South Korea, three in 2009 and one in 2008. The vessels are being acquired from companies controlled by Synergy Holdings for a total consideration of approximately $40M. The acquisition will be financed by bank debt, existing funds of the company and $6M raised in private placements. The company will also assume the charters the vessels are currently under. As part of the transaction, the company has agreed to acquire certain management services of Synergy Marine for the next three years. Andreas Papathomas, chairman of Synergy Holdings, has joined the board of the company. The company has also agreed to issue an additional $0.5M in shares of its common stock to Synergy Holdings if certain conditions are fulfilled in one year. One of the vessels was delivered to the company today while the remaining three are expected to be delivered within a week subject to certain closing conditions being met. The private placements of $6M of common stock are subscribed equally by Synergy Holdings and Eurobulk Marine. As the result of the private placements, the company will have issued approximately 8.45M new common shares at a price of 71c per share representing about 19% of the company's ownership after the acquisition. Euroseas believes that the addition of the four vessels will add in excess of $5M to the company's EBITDA over the next twelve months and reduce the average age of its fleet by approximately two years. After the acquisitions, the fleet of the company will reach 19 units which are all, except one, feeder and intermediate containerships, further highlighting the positioning of the company as the only publicly listed company focusing on the feeder and intermediate containership sector. In parallel with the vessel acquisition, the company announced that its vessel M/V Akinada Bridge, which has been drydocked in connection with its special survey, faced delays in completing the needed work resulting in the loss of the previously secured charter. The company has replaced the charter with another charter of similar rate and duration of three to five months which is expected to commence in early December when the remaining work on the vessel is expected to be completed.

16:11 EST BlueMountain reports 7.0% activist stake in AdaptHealth - BlueMountain Capital Management disclosed a 7.0% stake in AdaptHealth, which represents over 3.6M shares. The filing with the SEC allows for activism. BlueMountain said it may have discussions with AdaptHealth, other stockholders and third parties relating to the strategic alternatives that may be available to the company.

16:06 EST Airgain chosen as exclusive partner for Getac Video Solutions - Airgain announced that it has been chosen as the exclusive antenna provider for in-car video systems developed by Getac Video Solutions, which are used by police departments and public-safety agencies across the U.S. Airgain commenced production volume shipments to Getac in Q3 2019 with volume shipments expected to ramp through 2020.

16:05 EST Safehold signs pact to originate new $180M ground lease in NYC - Safehold Inc. announced it has entered into a definitive agreement with an institutional investment manager to create a new $180M Safehold ground lease under the office property at 685 Third Avenue in New York City. The transaction is expected to close in 2019, and is subject to customary closing conditions.

16:03 EST Frequency Electronics announces $3M contract award - Frequency Electronic announces the award of an approximately $3M contract for advanced technology oscillators for a US Government system. Under this contract, FEI will design and manufacture high performance oscillators and conduct associated qualification testing.Commenting on the award, FEI CEO, Stanton Sloane said, "We are pleased to have been selected for this program and that our advanced technology is being used to support critical US military systems."

15:51 EST Great Panther Silver reports fatality at Coricancha Mine Complex in Peru - Great Panther announces with great sadness that an employee lost his life in an accident that occurred during the late evening of November 17 at the processing plant of the company's Coricancha Mine Complex in Peru. The operation was undertaking further processing of stockpiles and limited mining, following the Bulk Sample Program completed earlier this year. There were no other injuries related to the accident. Great Panther's personnel immediately initiated protocols to close the plant area, and inform the employee's family and appropriate government and local authorities. The area of the accident has been barricaded and closed off while an investigation, which is underway, into the accident has been completed. "We are extremely saddened by this tragic accident and extend our deepest condolences to the family, friends and colleagues of our co-worker, an experienced plant operator who worked at the Coricancha Mine Complex for almost seven years", stated Jeffrey Mason, Interim President and CEO. "Safety is a core value at Great Panther and we will continue to strive to prevent such accidents from occurring. This includes completing an investigation of this accident and taking remedial action. Great Panther is continuing an in-depth review of its comprehensive safety policies, programs, and training across all operations."

14:59 EST LCNB Corp. raises dividend 5.88% to 18c per share - LCNB Corp. declared a fourth quarter dividend of 18c per share on the company's common stock. The dividend, which represents a 5.88% increase over the third quarter dividend, will be paid on December 16 to all outstanding shareholders of record December 2.

14:50 EST Globalscape trading resumes

14:41 EST GlobalSCAPE announces $3.35 per share special cash dividend, $5M buyback program - GlobalSCAPE announced it has entered into a five-year, $55M senior secured credit facility with a syndicate of banks led by J.P. Morgan. The new credit facility provides for a term loan facility in the principal amount of $50M and revolving commitments in an aggregate principal amount of $5M. The company also announced that its board of directors has authorized and declared a special cash dividend of $3.35 on each outstanding share of common stock. The record date for the special dividend is November 29, 2019, and the payment date for the dividend is December 5, 2019. Robert Alpert, Chairman of the Company's Board of Directors and Interim CEO, said, "I believe the new credit facility is a reflection of the Company's strong operating model and ability to generate significant free cash flow. Consistent with our goal of appropriately managing our capital structure, the Board of Directors authorized a special cash dividend of $3.35 per share of common stock as well as the repurchase of up to $5M of the company's outstanding shares. We will continue to consider other actions designed to enhance shareholder value."

14:26 EST Globalscape trading halted, news pending

14:03 EST Discovery rises after Malone buys $75M worth of stock - In a regulatory filing earlier with the SEC, it was disclosed that Discovery director John Malone purchased 2,670,000 shares of the company's Series C common stock on November 14 in a transaction with a value of $74,840,100. In afternoon trading following the disclosure of the stock purchase from the cable mogul, Discovery shares are up 85c, or 2.9%, to $30.57.

13:53 EST Bluestone Financial raises stake in McClatchy to 11.85% - Bluestone Financial holds an 11.85% stake in McClatchy as of November 18 after purchasing shares of common stock based on the belief "that The McClatchy Company shares represent an attractive investment opportunity," it was disclosed in a regulatory filing.

13:25 EST Altitude Sports files antitrust suit against Comcast - Altitude Sports & Entertainment, the official television network of the Denver Nuggets and Colorado Avalanche, filed a complaint in the U.S. District Court for the District of Colorado against Comcast Corporation and Comcast Cable Communications, LLC alleging that Comcast is illegally using its monopoly power in the Denver region to drive Altitude out of business, take over its license to air Nuggets and Avalanche games, and overcharge customers. The Denver region includes Colorado, Nebraska, Wyoming, and seven other states. Comcast, which reaches more than 50 percent of the television-watching homes in the Denver region, carried the Altitude network until August 31, 2019, when Comcast blacked out the network after Altitude refused to concede to predatory demands. Despite blocking their customers from watching Nuggets and Avalanche games, Comcast has continued to charge Denver-region families significant "Regional Sports" fees to provide them that coverage. Colorado Attorney General Phil Weiser recently announced that he is investigating Comcast's practice of charging its customers to watch games that Comcast is not actually showing. Based in Denver, Altitude and its parent, Kroenke Sports & Entertainment, employ a few thousand people across the Denver region. Altitude's complaint explains that Comcast has insisted on paying unjustifiably below-market fees to Altitude while unfairly charging Denver-region families to watch Altitude. Comcast has even demanded price increases to customers who want to watch Altitude, requiring Denver-region families to buy special premium packages that would mean many Denver-region families could not afford to watch their teams.

13:19 EST California sues Juul for lack of oversight on sales to minors - California Attorney General Xavier Becerra held a press conference to announce a lawsuit against Juul Labs. The state claims Juul failed to provide proper oversight when selling its electronic cigarettes to minors. California is asking for payment to address the costs of underage addiction, among other costs. "Juul adopted the tobacco industry's infamous playbook, employing advertisements that had no regard for public health and searching out vulnerable targets," Becerra said in a statement. "Today we take legal action against the deceptive practices that Juul and the e-cigarette industry employ to lure our kids into their vaping web." Altria Group (MO) owns a 35% stake in Juul.

13:11 EST California announces lawsuit against Juul for marketing to teens - Altria (MO) owns a 35% stake in Juul Labs

13:05 EST Whirlpool down 1% in afternoon trading - Contacts tell The Fly that data is being reported today from the Association of Home Appliance Manufacturers, or AHAM, which has the potential to move shares of the appliance maker.

12:48 EST Fortinet up 2% to $103.85 after issuing guidance at analyst day

12:39 EST Fortinet sees 'four key growth engines' growing to $60B market by 2023 - Fortinet, in analyst day presentation slides, said its "four key growth engines," or Secure Infrastructure, Cloud Security, Endpoint, IOT and OT Security, and Network Security, have a total addressable market of $45B in 2019. The company sees this growing 7% annually to $60B by 2023.

12:04 EST Viacom and CBS announce ViacomCBS corporate leadership - CBS (CBS) and Viacom (VIAB, VIA) announced additional senior appointments for ViacomCBS' corporate leadership. These appointments, which will be effective upon closing, "will align key functions and operations to support ViacomCBS' divisions and lines of business," the companies stated. Alex Berkett, Senior Vice President, Corporate Development & Strategy, Viacom, will become Executive Vice President, Corporate Development and Strategy; Nancy Phillips will serve as Executive Vice President, Chief People Officer; Marva Smalls, Executive Vice President, Global Head of Inclusion Strategy, Viacom, will serve as Executive Vice President, Global Head of Inclusion of ViacomCBS; Jose Tolosa, Chief Transformation Officer of Viacom, will expand his responsibilities as Executive Vice President, Chief Transformation Officer. These corporate leadership announcements follow the previously announced appointments of Christa D'Alimonte as Executive Vice President, General Counsel and Secretary; Anthony DiClemente as Executive Vice President, Investor Relations; DeDe Lea as Executive Vice President, Global Public Policy and Government Relations; Julia Phelps as Executive Vice President, Chief Communications and Corporate Marketing Officer, and Christina Spade as Executive Vice President, Chief Financial Officer. The merger of Viacom and CBS remains subject to customary closing conditions and is expected to close by early December.

12:00 EST Cango falls -10.6% - Cango is down -10.6%, or -72c to $6.10.

12:00 EST Medifast rises 8.7% - Medifast is up 8.7%, or $6.74 to $83.99.

12:00 EST CooTek rises 10.1% - CooTek is up 10.1%, or 57c to $6.23.

11:52 EST NeuroMetrix announces one-for-ten reverse split of common stock - NeuroMetrix announced the effectiveness of a one-for-ten reverse split of its common stock. The shares underlying the Company's outstanding options and warrants will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. As a result of the reverse stock split, every ten shares of the Company's common stock issued and outstanding at 5:00 pm on November 18, 2019 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.0001. No fractional shares will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof. Trading of the Company's common stock on the Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Tuesday, November 19, 2019, under new CUSIP number 641255807. Trading of the Company's listed warrants to purchase common stock on the Nasdaq Capital Market will also continue, on a split-adjusted basis, with the opening of the markets on Tuesday, November 19, 2019 under new CUSIP number 641255211. Shares of the Company's common stock and the Company's listed warrants to purchase common stock will continue to trade under the symbols "NURO" and "NUROW". Immediately subsequent to the reverse stock split, there will be approximately 978,175 shares of the Company's common shares issued and outstanding.

11:48 EST FCC Chair calls for public auction of 280 megahertz of C-band - FCC Chair Ajit Pai tweeted: "After much deliberation and a thorough review of the extensive record, I've concluded that the best way to advance these principles is through a public auction of 280 megahertz of the C-band conducted by the @FCC's excellent staff." The Fly notes that shares of Intelsat surged on November 15 after the C-Band Alliance, of which the company is a member, filed its U.S. Treasury contribution proposal stating that the CBA commits to pay a portion of net proceeds of a CBA-led auction to the U.S. Treasury using a progressive formula which ranges from 30% to 75% of proceeds depending on the outcome of the auction.

10:30 EST Snap up 4% to $14.47 after CEO ends interview on CNBC

10:29 EST Snap CEO says likely 10 years before spectacles are made for all day wear - Evan Spiegel is speaking on CNBC.

10:27 EST Snap CEO says maps will be more personal in the future - Evan Spiegel is speaking on CNBC.

10:26 EST Snap CEO says company will 'really invest' in augmented reality - Evan Spiegel is speaking on CNBC.

10:25 EST Gett announces closure of Juno, strategic partnership with Lyft - Gett announced the closure of its New York rideshare business, Juno, effective today, citing both Gett's increased focus on the corporate transportation sector and the enactment of misguided regulations in New York City earlier this year. Gett also announced a strategic partnership with Lyft to enable Gett's corporate clients to access rides in the United States beginning next year. Through the Lyft partnership, Gett's corporate customers traveling in the United States will be able to request rides through the Gett app and be matched with a driver on the Lyft network. Dave Waiser, Gett CEO, said, "Gett has a differentiated business model. With this announcement, we reinforce our position as the leading corporate transportation service. Instead of competing with consumer ridesharing companies, we are partnering with them. Our strategic partnership with Lyft is a win-win: Gett is expanding its reach across North America at the same time as we continue to see strong momentum in Europe, while Lyft benefits from the large number of Gett enterprise clients traveling to the U.S. Uniquely, Gett's SaaS solution aggregates a complete range of ground travel providers in-country and across geographies, on one single booking platform. Whether for ridesharing, chauffeur, limousine or taxi services, we provide enterprise clients with a best-in-class app and advanced back-end technology that consolidates all options across 100 countries, saving costs for clients globally. Gett's anticipated profitability is driven by our corporate SaaS solution, and we expect to be operationally profitable at a Group level in December of this year."

10:24 EST Snap CEO says all ads, including political, subject to review - Evan Spiegel is speaking on CNBC.

10:20 EST Snap CEO says 'I don't know' when asked if Facebook should be broken up - Evan Spiegel is speaking on CNBC.

10:18 EST Snap CEO says some of Facebook's actions could be viewed as anti-competitive - Evan Spiegel is speaking on CNBC.

10:13 EST Snap CEO says 'excited' about progress in growing communities - Evan Spiegel is speaking on CNBC.

10:00 EST Cango falls -11.9% - Cango is down -11.9%, or -81c to $6.01.

10:00 EST Medifast rises 7.3% - Medifast is up 7.3%, or $5.63 to $82.88.

10:00 EST VelocityShares 3x Inv Natural Gas ETN rises 8.9% - VelocityShares 3x Inv Natural Gas ETN is up 8.9%, or $9.75 to $118.90.

09:47 EST Rubicon Project falls -4.6% - Rubicon Project is down -4.6%, or -37c to $7.72.

09:47 EST Qudian falls -10.8% - Qudian is down -10.8%, or -81c to $6.69.

09:47 EST VelocityShares 3x Inv Natural Gas ETN rises 8.5% - VelocityShares 3x Inv Natural Gas ETN is up 8.5%, or $9.27 to $118.42.

09:38 EST T-Mobile CEO Legere reiterates 'board appointment extends beyond transition' - T-Mobile CEO Legere said, "I own no other color of clothing" and "I may just end up being a brand fanatic that owns 5% of the stock."

09:35 EST T-Mobile CEO says 'only restrictions on him are working for companies I hate' - After being asked if there are any restrictions on his exit, T-Mobile (TMUS) CEO John Legere joked that he can't "work for companies he hates," like Verizon (VZ) and AT&T (T).

09:32 EST T-Mobile CEO Legere says 'plenty of qualified candidates for CFO' - T-Mobile CEO John Legere said CFO Braxton Carter has continued to extend his contract multiple times through Legere's tenure and has extended through the CEO transition. Legere added that the company has plenty of qualified internal candidates and a few external ones that are being considered to "fill the rather large, pink cowboy hat."

09:29 EST Acacia Research to receive up to $400M in new capital from Starboard partnership - Acacia Research announced a strategic partnership with Starboard, a New York-based investment adviser. This financing will provide Acacia with access to up to $400M of new capital for strategic investments and acquisitions, and Starboard will work directly with Acacia to identify and execute on these opportunities. Starboard has made a $35M investment in Acacia, acquiring 350,000 shares of Series A convertible preferred stock convertible at $3.65 per share, a 38% premium to Acacia's 30-day trailing volume-weighted average price, or VWAP, and warrants to purchase five million shares of common stock with an exercise price of $3.65 per share. Acacia may issue up to $365M in senior secured notes due 2027 with a cash interest rate of 6% to Starboard, the proceeds of which may be used to fund investment opportunities and strategic acquisitions approved from time to time by the company and Starboard. Promptly upon the receipt of Acacia stockholder approval, Starboard will purchase warrants to purchase up to 100M shares of the company's common stock at a cash exercise price of $5.25 per share or by the cancellation of notes, to the extent the notes have been issued, at an exercise price of $3.65 per share. Acacia has reserved the right to offer existing Acacia common stockholders the opportunity to purchase up to $100M in notes and 27M warrants on substantially the same terms of the Notes and Series B Warrants. Jonathan Sagal, managing director of Starboard, has joined Acacia's baord and Starboard Value has certain other board appointment rights. Under the terms of the transaction agreements, Starboard has purchased 350,000 preferred shares, with a liquidation preference of $100 per share and an initial cash dividend rate of 3%, and Series A warrants to purchase up to five million shares of common stock, resulting in proceeds to Acacia of $35M. The conversion price of the preferred shares and the exercise price of the Series A warrants is $3.65. These proceeds will be held in escrow until used for an approved investment. Following the use of the proceeds to fund a strategic investment or acquisition, the dividend rate on the Preferred Shares will increase to 8%. The transaction also establishes a structure by which the company and Starboard may agree on approved investments from time to time to be financed by notes in an aggregate principal amount up to $365M with a 6% annual interest rate. Acacia will seek stockholder approval for the company's issuance of the securities described in the transaction agreements without giving effect to any limitations under the rules of Nasdaq and an amendment to its certificate of incorporation to increase the number of authorized shares of common stock to 300,000,000 shares. After the receipt of stockholder approval, Starboard will also purchase Series B Warrants to purchase up to 100 million shares of common stock at a cash exercise price of $5.25 until 30 months after their issuance date. The Series B warrants may also be exercised by the cancellation of outstanding notes at an exercise price of $3.65 per share at any time after the notes have been issued until the maturity date of the notes. The preferred shares, notes and warrants all contain limitations on conversion or exercise, such that Starboard may not convert or exercise its securities into greater than 4.89% of Acacia's outstanding common stock. The preferred shares contain and the notes, if and when issued, will contain, affirmative and negative covenants customary for transactions of this type, including but not limited to, limitations on the company's ability to incur debt, grant liens on its assets, make certain distributions in respect of its equity and make certain investments. Acacia's board intends to offer $100M of notes and warrants to purchase up to 27M shares of common stock, with substantially identical terms as the notes and Series B warrants held by Starboard, to Acacia's common stockholders. The company, subject to the board's discretion, intends to effect this through one or more rights offerings to stockholders of record on each date that an approved investment to be funded by the sale of notes to Starboard is announced. The company has entered into a governance agreement with Starboard whereby Jonathan Sagal of Starboard has joined the board and has the right to appoint two additional directors to the board.

09:25 EST ClearOne begins shipping of CONVERGENCE AV Network Manager - ClearOne announced it has begun the worldwide shipping of its new CONVERGENCE AV Network Manager; a unified AV network management platform to monitor, control, and audit ClearOne Pro Audio and Video products and services - beta now available for download. The cross-platform server runs on Windows and Linux OS for seamless IT integration and remote real-time system access provides at-a-glance and all-inclusive dashboard views.

09:23 EST Terreno Realty acquires property in Seattle, WA for $2.9M - Terreno Realty acquired an industrial property in Seattle, Washington on November 15 for a purchase price of approximately $2.9M. The 0.9-acre improved land parcel at 5200 East Marginal Way South is immediately adjacent to Terreno Realty Corporation's property at 53 South Dawson and is adjacent to Seattle's Port and SoDo District. The property is vacant and the estimated stabilized cap rate is 5.6%. Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer's due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

09:21 EST SoftBank chooses Fortinet Secure SD-WAN to accelerate managed SD-WAN services - Fortinet (FTNT) announced that SoftBank Corp. (SFTBY) has chosen Fortinet Secure SD-WAN to accelerate and expand its portfolio of managed SD-WAN services to help enterprise customers keep up with the pace of digital innovation. The addition of Fortinet's carrier-grade secure SD-WAN solution allows SoftBank to increase the security posture of enterprise customers by minimizing the attack surface, provide greater business agility with faster on-boarding, and simplify operations.

09:18 EST Prevail Therapeutics appoints Morgan Sheng to board of directors - Prevail Therapeutics announced the appointment of Morgan Sheng, Ph.D., to its Board of Directors. Sheng is a Core Institute Member and Co-Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. He is also a Professor in the Department of Brain and Cognitive Science at MIT.

09:17 EST LogMeln, Bitdefender partner for antivirus feature - LogMeIn announced it is joining forces with Bitdefender to power LogMeIn Antivirus, a recently released feature available to LogMeIn Central customers. Through the partnership with Bitdefender, LogMeIn AV delivers a robust and reliable antimalware solution designed to protect against viruses, malware and sophisticated online threats. Fully integrated into Central Premier and the Central Security module at no additional cost, customers can configure and deploy the antimalware feature while also benefiting from the consolidation of their antimalware into Central.

09:16 EST The Medicines Co. announces ORION-9 met all primary, secondary endpoints - The Medicines Co. announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol, or LDL-C, lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA class. In ORION-9, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and demonstrated an excellent safety profile. Full study results were presented during a late-breaking science session at the American Heart Association, or AHA. For the primary endpoints of ORION-9, inclisiran delivered placebo-adjusted LDL-C reductions of 50% at day 510 in HeFH patients and demonstrated time-averaged placebo-adjusted LDL-C reductions of 45% from days 90 through 540. The overall adverse event profiles of the placebo- and inclisiran-treated groups in ORION-9 were similar. At least one serious treatment emergent adverse event was experienced by 13.8% of patients in the placebo-treated group and 7.5% of patients in the inclisiran-treated group. The incidences of deaths and malignancies were similar between the placebo and inclisiran groups, respectively. Low incidences of clinically significant elevations in liver function tests and serum creatinine increases were observed in the placebo and inclisiran groups, respectively, and none were considered related to study drug. Clinically relevant adverse events at the injection site, predominantly mild and always transient, were reported in 0.4% of placebo-treated patients vs. 13.7% of inclisiran-treated patients. ORION-9 data will be submitted to a peer-reviewed medical journal. The company expects to file regulatory submissions in the U.S. in Q4 and in Europe in Q1 of 2020.

09:13 EST Amazon announces second fulfillment center in Mississippi - Amazon.com announced plans for its second Mississippi fulfillment center, to be located in DeSoto County. The facility will create 500 new, full-time jobs starting at $15 an hour with comprehensive benefits starting on day one. In addition, Amazon has pledged to invest over $700 million to provide upskilling training for 100,000 U.S. employees for in demand jobs. Programs will help Amazonians from all backgrounds access training to move into highly skilled roles across the company's corporate offices, tech hubs, fulfillment centers, retails stores, and transportation network, or pursue career paths outside of Amazon. All associates will go through hours of safety training and have access to continuing education opportunities through Amazon's upskilling programs such as Career Choice. In this program, the company will pre-pay up to 95 percent of tuition for courses related to in-demand fields, regardless of whether the skills are relevant to a career at Amazon. Since the program's launch, more than 25,000 employees have pursued degrees in game design and visual communications, nursing, IT programming and radiology, to name a few.

09:11 EST Cytokinetics, Amgen, Servier announce results from COSMIC-HF Phase 2 trial - Amgen (AMGN), Cytokinetics (CYTK) and Servier announced that new results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, will be presented today at the American Heart Association's Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures, measures of diastolic function were not different from placebo and, for some measures, trended towards improvement. In COSMIC-HF, 448 patients with stable, symptomatic heart failure and left ventricular ejection fraction less than40% were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks. This post-hoc analysis assessed the effect of chronic therapy with omecamtiv mecarbil by treatment group on echocardiographic measures of diastolic function, including early and late peak mitral inflow velocities, early peak myocardial relaxation velocity, isovolumic relaxation time, tricuspid regurgitation velocity and diastolic filling time. In patients with HFrEF who received omecamtiv mecarbil, systolic ejection time increased as previously reported and expected, while diastolic filling time was not reduced, nor were diastolic parameters worsened. Specifically, in patients receiving omecamtiv mecarbil E-wave velocity, E/A-ratio, and E/e' or e' were not significantly changed compared to placebo. There was a small increase in the duration of the IVRT, and in the PK group, TRV, an indicator of pulmonary pressure, improved significantly during treatment with omecamtiv mecarbil therapy

09:10 EST Fly Intel: Pre-market Movers - HIGHER: Qiagen (QGEN), up 3% after announcing late on Friday that the company is exploring potential strategic alternatives following "several conditional, non-binding indications of interest"... NIO Inc, (NIO), up 4% after appointing Wei Feng as CFO... Teekay Tankers (TNK), up 3% after BofA Merrill Lynch analyst Ken Hoexter issued a double-upgrade on shares to Buy from Underperform with a price target of $3, up from $2... Karuna Therapeutics (KRTX), up 72% after KarXT met its primary endpoint in a Phase 2 trial... Yandex (YNDX) up 6% after announcing a $300M share repurchase program. DOWN AFTER EARNINGS: Quidian (QD), down 8%. ALSO LOWER: T-Mobile US (TMUS), down 2% after announcing that Mike Sievert, who is currently President, COO and a director, will assume the CEO role from John Legere after the conclusion of Legere's contract on April 30, 2020... SunPower (SPWR), down 4% after filing to sell 22M shares of common stock... Xerox (XRX) and HP Inc, (HPQ), down 2% and 1%, respectively, after HP announced that its board has unanimously rejected the unsolicited acquisition proposal from Xerox... Ultra Clean (UCTT), down 2% after Stifel analyst Patrick Ho downgraded the stock to Hold from Buy with an unchanged price target of $21. The analyst says the downgrade is "based entirely on valuation".

09:07 EST Shutterstock names Jarrod Yahes as CFO, effective December 9 - Shutterstock announced Jarrod Yahes is joining the company as CFO, effective December 9. Yahes brings more than 20 years of financial experience to Shutterstock. He is an accomplished executive having previously built finance and accounting teams, executed an IPO and led numerous strategic mergers and acquisitions. Additionally, Yahes has significant experience with public-company controls, reporting processes and investor relations. Since October 2016, Yahes has served as the CFO at Zeta Global, a marketing technology company. Previously, he was the CFO at Jackson Hewitt.

09:06 EST Amarantus CEO sees areas for 'collaborations that could accelerate growth' - Amarantus Bioscience released a letter to its shareholders following the announcement of the binding term sheet to license the Company's therapeutics subsidiaries' technologies to Emerald Organic Products. The letter read, in part, "I am pleased to provide an update regarding progress on several fronts and on the plan to deliver a recapitalization of the Company that would allow for shareholders to benefit from the value of Amarantus' exciting portfolio. Our goal has been to place our development programs into separate subsidiary companies, and then work with partners to attract financial resources to advance these programs through FDA approval and into commercialization via those subsidiaries. This plan would also allow for the settlement of the Company's outstanding liabilities and potentially provide significant upside for Amarantus shareholders. As previously announced, we entered into joint venture via our Breakthrough Diagnostics subsidiary with Todos Medical, Ltd. to develop our neurodiagnostics technologies, led by blood screening diagnostic LymPro Test for Alzheimer's disease, and we have agreed to license our therapeutic portfolios to Emerald Organic Products. These transactions provide a promising path forward for our programs. Amarantus will own Todos common shares equating to approximately 49% of Todos common shares immediately prior to Todos completing a capital raise to list its common shares on the Nasdaq Capital Markets, and Amarantus will own convertible preferred stock with a face value of $100M in Emerald upon closing of the pending license agreement of our therapeutics portfolio to Emerald. The Company will also receive royalties from product sales. Amarantus also continues to hold a 31.5% common equity position in Avant Diagnostics, which was taken private in first half of 2019. Avant is preparing to relaunch the Theralink(R) phosphoprotein tumor analysis platform back into the marketplace in 2020. I am also confirming our plans remain to complete our capital restructuring by conducting a capital raise via Reg A. In addition, Amarantus management has begun to evaluate the timing, amount and record date of a potential dividend of a portion of the shares Amarantus receives from Todos to its common shareholders. This dividend assumes the successful completion of the Breakthrough acquisition by Todos and related uplisting of Todos common shares to Nasdaq CM, and would be tangible recognition of ongoing support of Amarantus by its shareholders...We are encouraged by the progress in recent months and the strength of the opportunities to move our programs forward. We see significant synergy in our product and IP portfolios, and see areas for potential collaborations that could accelerate growth."

09:05 EST BAE Systems awarded $71M in contracts for aircraft survivability equipment - BAE Systems has received contracts to deliver $71M in aircraft survivability equipment to several U.S. allies via U.S. Army Foreign Military Sales. Under the contracts, the Netherlands, Spain, the United Kingdom and the United Arab Emirates have agreed to purchase the AN/AAR-57 common missile warning system, or CMWS, and associated equipment to protect their aircraft and crews from sophisticated threats. CMWS is designed to detect a wide range of infrared-guided missiles and hostile fire threats, providing warnings to pilots and cueing laser-based and expendable countermeasures. The system's rapid response capabilities improve survivability and reduce the cognitive load on pilots.

08:55 EST Acasti Pharma releases preliminary animal data on CaPres mechanism of action - Acasti Pharma released some preliminary new animal data which provides additional insights into CaPre's potential mechanism of action in diabetes. In the Company's Phase 2 studies in humans, a statistically significant reduction of hemoglobin A1c was seen in the 4 gram treatment arm of the COLT study. This is the same dose that is currently being tested in Acasti's TRILOGY Phase 3 program in humans. This positive HbA1c result In COLT was surprising at the time, and potentially unique to CaPre, as other therapeutic OM3s had previously shown no effect on glucose metabolism in a diabetic or pre-diabetic population. The main objective for this new mechanistic diabetes mouse study was to assess if CaPre acts on glucose and/or insulin in some unique manner, and to compare results head-to-head with icosapent ethyl, a marketed omega-3 therapeutic, and metformin, a widely prescribed diabetic medication. Acasti collaborated with Professor Andre Marette, Ph.D. who conducted the study. Dr. Marette, who is the Director of the Pfizer Chair to study the pathogenesis of insulin resistance and cardiometabolic diseases at the University Laval, Quebec, conducted the study for Acasti in a widely used and well accepted animal model in diet-induced obese C57BL6 mice to compare the mechanisms of action of CaPre versus icosapent ethyl and metformin on insulin resistance and type 2 diabetes. A second, still ongoing study will also compare these same drugs in a fatty liver disease animal model. Dr. Marette is a highly regarded researcher of cardiometabolic disease, and he has published numerous papers in prestigious journals such as Nature Medicine. The preliminary findings obtained for the diabetes mouse study showed that CaPre may promote insulin secretion as seen by statistically significant results produced in a standard glucose challenge test, thus suggesting a mechanism of action different and unique when compared to metformin, which does not promote insulin secretion. Furthermore, icosapent ethyl showed no effect on insulin or any improvement in glucose metabolism or management. Key additional findings from this diabetic mouse study are: CaPre increased insulin production in association with increased c-peptide levels, suggesting that this effect is linked to greater insulin secretion by ss cells. This was also associated with a tendency for lower glucose responses during a glucose challenge test. CaPre exhibited a dose response, where the higher the dose the more insulin was secreted. Both CaPre and icosapent ethyl significantly increased plasma 18RS-HEPE, as compared to the untreated control and metformin groups. Despite the lower levels of EPA in CaPre's composition, the actual levels of 18RS-HEPE reached in the blood were higher for CaPre than levels produced by icosapent ethyl. Again, a dose response effect was seen with CaPre. 18RS-HEPE and Resolvin E1 are both resolving mediators of OM3s, and particularly EPA, and they are involved in the resolution of inflammation that is triggered in many chronic diseases including obesity and diabetes. Both high dose, and low dose of CaPre significantly increased plasma levels of 17S-HDHA and PDX as compared to the untreated control group. The effects of high dose CaPre on PDX was very robust and significant, and much greater than those of icosapent ethyl, which showed virtually no response. Research has shown that increased levels of PDX improves insulin sensitivity in various models of insulin resistance and diabetes by several mechanisms, including by limiting inflammation in metabolic tissues, as well as by enhancing skeletal muscle IL-6 secretion, AMP activated protein kinase activation and glucose uptake, and by enhancing insulin's ability to suppress hepatic glucose production, which is also elevated in diabetic patients. Data from the diabetic mouse study are still being compiled and finalized. The second study underway in a fatty liver/NASH disease model, will further confirm the findings of the diabetes study, and may potentially provide more insight into the mechanism of action of CaPre on the plasma lipid profile, and in fatty liver disease by further comparing the impact of CaPre on plasma TGs, LDL-C and HDL-C, as well as on hepatic lipid accumulation versus that of icosapent ethyl and metformin. Based on the findings from both of these study phases, Acasti and Dr. Marette plan to submit the data to a peer review journal for publication. Acasti may also file additional patents covering unique aspects and applications of this expanded understanding of CaPre's mechanism of action.

08:51 EST Artelo announces publication of fatty acid binding protein 5 inhibitor data - Artelo Biosciences announced that positive non-clinical data with the Company's Fatty Acid Binding Protein 5 inhibitor program under development in collaboration with The Research Foundation of the State University of New York Stony Brook, were published in the October 2019 issue of The Prostate, a premier peer-reviewed journal. Prostate cancer remains the second leading cause of cancer-related death among men. Taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy naive castration-resistant prostate cancers. However, tumors often develop resistance to taxanes, and taxane-treatment can lead to numerous adverse effects that can lead to the termination of therapy. FABP5 is an intra-cellular protein chaperone that serves as a carrier for fatty acids that trigger increased expression of genes associated with tumor angiogenesis and reduced patient survival. Inhibition of FABP5 has previously been shown to suppresses the growth and migration of breast and prostate cancers. Researchers at Stony Brook University assessed whether FABP5 inhibitors synergize with semi-synthetic taxanes to induce cytotoxicity in vitro and attenuate tumor growth in vivo.

08:47 EST Spark Networks CEO Jeronimo Folgueira to step down, Eric Eichmann to succeed - Spark Networks (LOV) announced the appointment of Eric Eichmann as CEO, effective November 18. Eric will replace Jeronimo Folgueira who is stepping down from the role as CEO. To ensure a smooth transition, Jeronimo will remain with Spark Networks through the end of 2019 and will continue to serve on Spark's board of directors. Previously, Eric Eichmann was CEO at Criteo (CRTO).

08:44 EST Tabula Rasa HealthCare announces pharmacy services agreement with WelbeHealth - Tabula Rasa HealthCare will provide medication safety and comprehensive pharmacy services to WelbeHealth, through an agreement with its subsidiary CareKinesis. TRHC already provides health plan management services to WelbeHealth through its PeakTPA service line; both PeakTPA and CareKinesis operate as part of TRHC's CareVention HealthCare Division. WelbeHealth, founded by mission-driven physicians to unlock the full potential of the most vulnerable seniors in underserved communities, opened its first two PACE programs in 2019 in the Stockton-Modesto and Pasadena-Glendale-Burbank regions of California. The company plans to open additional locations in 2020 that also will adopt TRHC services including both health plan management and pharmacy services.

08:42 EST Sirius International Insurance Group confirms Frucher as Non-Executive Chairman - Sirius International Insurance Group announced that its Board of Directors confirmed Meyer Frucher as Non-Executive Chairman of the Board of Directors of the company. Frucher was previously appointed as an interim Non-Executive Chairman of the Board.

08:40 EST Capstone Turbine announces 1 MW project in Colombia with Ecopetrol - Capstone Turbine announced it secured its first-ever flare gas project in Colombia with Ecopetrol. Supernova Energy Services, Capstone's exclusive distributor for Colombia and Venezuela, secured the order for the 1 megawatt, or MW, project, which is expected to be commissioned by the end of the year. Ecopetrol is one of the largest oil producers in the world, with multiple hydrocarbon extraction fields throughout Colombia. Looking to replace one of its reciprocating engine generators in the Rio Ceibas Field, engineers turned to Capstone's regional distributor.

08:39 EST CytoDyn engages LifeSci Public Relations as communications partner - CytoDyn announced that it has engaged LifeSci Public Relations to increase awareness of the Company's brand, science and clinical programs. LifeSci Public Relations will provide CytoDyn with integrated communications services through strategic messaging, media outreach, and social and digital media efforts.

08:37 EST ServiceNow appoints Gina Mastantuono as CFO, says CEO has assumed role - ServiceNow announced that Gina Mastantuono will join ServiceNow as CFO, effective January 13, 2020. Mastantuono joins the company from Ingram Micro, where she served as CFO. Mastantuono brings more than 20 years of financial experience to ServiceNow, including in the cloud, IT and mobility solutions industries. Since 2016, she has served as CFO of Ingram Micro, a provider of global technology and supply chain services with more than $50B in revenue in FY18 and 200,000 customers worldwide. Mastantuono led the company's global finance organization, including financial planning and analysis, M&A, treasury and risk management, accounting and reporting, internal audit, tax, investor relations and global business processes. ServiceNow announced on October 22 that Bill McDermott is joining the company as president and CEO by year-end, succeeding president and CEO John Donahoe, who is stepping down to become CEO of Nike. McDermott has now formally assumed the role of president and CEO and joined ServiceNow's board of directors. Donahoe will continue to serve on ServiceNow's board through his current term, which ends in June 2020.

08:35 EST T-Mobile down 1.6% after announcing CEO transition

08:34 EST Future FinTech announces agreement with Chifeng Supply and Marketing Company - Future FinTech announced cooperation with Chifeng Supply and Marketing E-commerce Co. to develop a blockchain contract farming platform focusing on sheep farming. Contract farming is defined as a sales arrangement of certain agriculture products between a customer and a farmer before production begins and it establishes conditions for the production and markets for farm products. By connecting the consumers and farmers directly, contract farming can offer farmers an assured market and offer consumers higher food quality and safety. The first phase of the blockchain contract farming platform will focus on sheep farming in Chifeng. Future FinTech agreed to utilize its technology to develop and provide the real-name blockchain platform for the contract sheep farming. Chifeng Supply and Marketing Company will consolidate local farmers and resources to transform them into standard sheep farming. By building a blockchain contract farming platform, every sheep farming process will be carried out by a real-name farmer and record on the blockchain. Consumers would be able to track the whole standard sheep farming process.

08:32 EST Enlivex Therapeutics completes recruitment in Phase Ib trial of Allocetra - Enlivex Therapeutics reported completion of patient recruitment into the Company's Phase Ib clinical trial in patients with severe sepsis. The study was designed to recruit ten patients, including six treated with a single dose of Allocetra, and four patients treated with two doses of Allocetra. Enlivex announced on November 4, 2019 positive interim safety and efficacy data from an ongoing trial of off-the-shelf universal Allocetra in patients with severe sepsis. The interim analysis comparing the first six Allocetra-treated patients with 37 severe sepsis patients with equivalent source of infection and disease severity who were hospitalized at the same hospital, demonstrated the potential of single dose Allocetra infusion as therapy for prevention of sepsis-associated organ failure and mortality. ALLOCETRA by Enlivex was designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including prevention or treatment of complications associated with bone marrow transplantations and/or hematopoietic stem cell transplantations; organ dysfunction and acute multiple organ failure associated with sepsis; and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing.

08:32 EST Amyris moves into regulatory stage with new health and nutrition molecule - Amyris announced that it is moving into the regulatory stage with a new, undisclosed health and nutrition molecule. Amyris has proven its capability to produce health and nutrition molecules at commercial scale with three others; artemisinin, vitamin E and, most recently, Reb Amyris developed a process for this ingredient that enables the highest purity at the lowest cost and has now successfully manufactured material via large scale fermentation. The company plans to submit formal regulatory filings for this ingredient (currently not being named due to partner's requirements) where required for rapid approval and market entry during the first half of 2020.

08:29 EST Cooper Companies announces FDA approval of MiSight for treatment of myopia - CooperCompanies announced that CooperVision has received U.S. Food and Drug Administration approval of its MiSight 1 day contact lens, indicated to slow the progression of myopia when initially prescribed for children 8-12 years old. MiSight 1 day has been scientifically proven to reduce myopic progression by up to 59%. This is the first FDA approved myopia management contact lens and is expected to be available in the U.S. beginning in March of 2020.

08:26 EST Seelos Therapeutics receives FDA Fast Track designation for SLS-002 - Seelos Therapeutics announced the U.S. Food and Drug Administration has granted Fast Track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder. Data from a Phase I study of SLS-002 to evaluate the pharmacokinetics, pharmacodynamics, and drug-drug interactions is expected in the first quarter of 2020.

08:24 EST Xunlei collaborates with China Tower Corporation on edge computing project - Xunlei Limited announced that the Company and the Shaanxi subsidiary company of China Tower Corporation have entered into an agreement to jointly develop an edge computing project. Under the agreement, Xunlei and China Tower Shaanxi subsidiary will start an edge computing project in Shaanxi province to deploy the initial computing nodes at 10,000 cellular tower stations. Taking advantage of each other's strengths, the parties intend to cooperate in areas including edge computing, IoT and blockchain, and jointly build an edge computing and IoT ecosystem to facilitate the development of information system for other industries in the era of 5G technology. Founded in 2014, China Tower Shaanxi subsidiary operates approximately 70,000 cellular transmission stations and with total assets of approximately RMB10B. With widely distributed cellular transmission tower resources, China Tower Shaanxi subsidiary recently accelerated its business development by actively seeking business opportunities in IoT, big data, edge computing, artificial intelligence, and other information and communications service industries.

08:21 EST NV5 Global announces $20M owner's representative contract in California - NV5 Global announced the award of a four-year contract by a San Francisco Bay Area municipality to provide owner's representation, design oversight, plan review, and field inspection services on a 240 acre mixed use redevelopment project. The $8B project includes over nine million square feet of office, retail, dining and entertainment space, hotels, and more than 1,600 residential units and apartments. NV5's initial assignment under the flexible services agreement is for $5M. We anticipate this engagement will exceed $20M in multi-vertical services as the project progresses. Because the site is being developed over a closed landfill, it poses complex design and construction challenges. NV5's contract scope includes plan review and inspection services related to electrical transmission and distribution, landfill, parks and recreation, public works, and water operations and maintenance. Vertical construction of the project will begin in early 2020, and the first phase of the project is scheduled for completion in 2023

08:18 EST Centogene, PTC Therapeutics collaborate for global diagnostic testing program - Centogene (CNTG) announced that it has signed an agreement with PTC Therapeutics (PTCT) for a global diagnostic program for aromatic L-amino acid decarboxylase deficiency. The testing program for AADC deficiency will provide physicians with much needed analysis of 3-O-Methyldopa, a powerful metabolic biomarker measured by mass spectrometry. When indicated by abnormal 3OMD levels, next generation sequencing of the dopa decarboxylase gene and variant analysis - providing 100% coverage - will be conducted. Eventually, deletion/duplication analysis will then be run if no mutation is identified via NGS. Analysis will be performed using CentoCard - CENTOGENE's CE-marked dried blood spot collection kit - that will be directly shipped to physicians. CENTOGENE also is in the process of validating DDC enzyme activity from dried blood spot and in doing so aims to offer 3OMD, NGS and DDC enzyme activity testing using a single CentoCard. This represents a complete set of assays facilitating the diagnosis of AADC.

08:12 EST H-CYTE raises $6M to accelerate FDA process for cellular therapy - H-CYTE announces it has raised $6M in new funding. The investment is in the form of preferred stock which may be converted into shares of common stock at a fixed price in excess of the current market, at approximately $.41 per share. The investment was led by a group that includes Todd Wagner, a co-founder of Broadcast.com and Rex Farrior and Preston Farrior, prominent philanthropists and University of Florida benefactors. The new funding will be used to advance the company's development of industry-leading medical treatments for chronic lung diseases such as COPD. H-CYTE recently entered into a long-term agreement with Rion that will enable H-CYTE to develop proprietary biologics for treatment of COPD. The company is planning on pursuing submission of an investigational new drug application for review by the U.S. Food and Drug Administration for that new treatment. The new funding was completed in a purchase of H-CYTE Series D Preferred Stock by FWHC LLC, an investment group that consists of Wagner as well as Tampa natives Rex Farrior and Preston Farrior. Additional details of the transaction will be filed in a Form 8K filed with the Securities and Exchange Commission.

08:10 EST NanoVibronix: PainShield device receives unique reimbursement code from CMS - NanoVibronix announced that the Centers for Medicare and Medicaid has assigned a unique, Level II product reimbursement code under the Healthcare Common Procedure Coding System for use in 2020. HCPCS code K1004 will help facilitate reimbursement for the use of PainShield.

08:08 EST Eros International entertainment platform announces collaboration with YouTube - Eros Now, a South Asian OTT entertainment platform with more than 177M registered users owned by Eros International (EROS), announced a collaboration with YouTube (GOOG) Music in India. As part of the collaboration, a special Eros Now subscription package priced at 99 Indian Rupees for 90 days will be made available to all new subscribers of YouTube Music premium and Google Play Music in India. At the end of the three month introductory offer, the customer will be charged separately as per prevailing plans for Eros Now and INR 99 per month for YouTube Music Premium. With Eros Now's content library of 12,000+ movies, TV shows and short-format content, users will also get access to YouTube Music's catalogue including tracks in English, Hindi and nine other Indian languages.

08:06 EST Integer updates 2019 guidance following Nuvectra Chapter 11 filing - Integer Holdings Corporation (ITGR) announced the following related to the Chapter 11 filing of Nuvectra Corporation (NVTR), a customer of Integer, on November 12, 2019: Estimated 4Q19 asset impairment charge and other costs of approximately $24M pre-tax, primarily non-cash ; Lowered 2019 sales guidance by $12M on the low and high end of range; lowered 2019 GAAP income and earnings per share guidance, but no change in non-GAAP adjusted EBITDA, adjusted income and adjusted EPS guidance; The Nuvectra bankruptcy filing does not change Integer's prior view of its 2020 sales outlook.Integer will incur an estimated $24M in pre-tax asset impairments and related charges, primarily non-cash and related to inventory, supplier obligations and accounts receivable. These charges will impact Integer's GAAP financial results, thereby reducing GAAP income guidance by $19M. The revised GAAP income range is expected to be $87M to $91M and GAAP EPS of $2.65 to $2.75. These impairment and related charges will be excluded from Integer's non-GAAP adjusted results to provide investors a more comparable view of Integer's operating performance for 2019 and to serve as a baseline for 2020. Nuvectra communicated to its vendors to "cease providing all products" under its court-supervised process. This lowers Integer's fourth quarter sales outlook by $12M, which is now expected to be at the low end of a revised sales guidance range of $1,253M to $1,268M for full year 2019. The $12M reduction in 4Q19 Nuvectra sales would be expected to negatively impact Integer's adjusted EBITDA by approximately $4Mn. However, through continued progress in its manufacturing excellence strategic imperative and operating expense management in the fourth quarter, the company maintains its prior adjusted EBITDA guidance range of $282M to $286M though it expects to be on the low end of that range. The adjusted EPS guidance also remains unchanged at $4.55 to $4.65. The Nuvectra bankruptcy filing does not change Integer's prior view of its 2020 sales outlook. Integer still expects to grow at "market growth rates" in total but is reducing the impact of the neuromodulation market slow down and supply agreements to a $10M headwind in 2020, down from a $20M headwind outlined in its third quarter earnings call on October 31, 2019. Integer's prior 2020 sales outlook had already considered the full range of potential outcomes of Nuvectra's announced "strategic alternatives" evaluation disclosed in August 2019. Integer intends to preserve its rights and pursue available legal remedies to recover any losses suffered as a result of Nuvectra's Chapter 11 filing.

08:04 EST Six Flags increases quarterly dividend 1% on annualized basis to 83c per share - Six Flags announced that its board of directors declared a Q4 cash dividend of 83c per share of common stock payable to shareholders of record as of November 29. The dividend will be paid December 9. The new dividend represents a 1% increase on an annualized basis, and the company's tenth increase over the last nine years. Since 2010, the company has returned more than $3.7B to shareholders in the form of dividends and share repurchases.

07:59 EST AerCap, EGYPTAIR execute leases for two Boeing 787-9 aircraft - AerCap (AER) and EGYPTAIR announced they have executed long-term operating leases for two Boeing (BA) 787-9 aircraft. The aircraft are from AerCap's order book with Boeing and the first unit is scheduled to deliver in 2021 with the second unit delivering in 2022. In October 2017, EGYPTAIR placed an order with AerCap for six 787-9 aircraft, all of which were delivered to the airline in 2019.

07:52 EST Telesat Canada announces proposed amendment to existing credit agreement - Telesat Canada announced that it entered into discussions on November 15, 2019 to amend its existing credit agreement, dated March 28, 2012, among Telesat and Telesat LLC, as borrowers, the guarantors party thereto, the lenders party thereto from time to time, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent for the secured parties and the other financial institutions party thereto. The proposed amendment would extend the maturity of the Term Loan B facility and the Revolving facility under the Existing Credit Agreement, as well as make certain other amendments. As of September 30, 2019, the Borrowers had approximately $2.3B outstanding under the Term Loan B facility and up to $200M available under the Revolving facility. In connection with the amendment, Telesat expects to repay a portion of the Term Loan B borrowings. Telesat also announced that, together with Telesat LLC, as co-issuer, it intends to issue $500M of senior secured notes due 2027 secured by a first priority lien on the collateral that secures the Existing Credit Agreement. Telesat intends to use the net proceeds from the proposed offering of Senior Secured Notes to repay a portion of the Term Loan B borrowings outstanding under the Existing Credit Agreement and pay related fees and expenses. Privately held, Telesat's principal shareholders are Canada's Public Sector Pension Investment Board and Loral Space & Communications.

07:46 EST Sintx Technologies CEO says company has 'enormous potential and a bright future' - CEO B. Sonny Bal said, "The key goals as we head into 2020 are to maintain our leadership in silicon nitride technology and develop new OEM revenue opportunities through strategic initiatives. We will maintain fiscal discipline, while making progress toward break-even cash flow. With multiple interested partners scrutinizing the Company, established investment banking relationships, a broad technology portfolio, an array of new technologies under development, and an experienced team, we believe that SINTX Technologies has enormous potential and a bright future."

07:38 EST Acreage to acquire Compassionate Care Foundation of New Jersey - Acreage Holdings announced that on November 15, certain of its subsidiaries and Compassionate Care Foundation, a New Jersey vertically integrated cannabis nonprofit corporation, entered into a Reorganization Agreement, pursuant to which Acreage will acquire 100% of the equity interests in CCF, and subsequently consolidate their financials. Closing of the transaction is subject to state approval.

07:37 EST Stein Mart launches fine jewelry department in 51 stores - Stein Mart announced it has launched a fine jewelry department in 51 stores and online, as well as a key item fine jewelry program in all stores. This news follows the company's announcement of its new Kids department. The fine jewelry collection, called "Stein Mart Jewel Box", features beautiful diamonds, pearls, 14K gold, gemstones and designer branded jewelry with prices ranging from $200 to $5000. At 40-60% off competitors' prices, Stein Mart's fine jewelry is sure to satisfy any shopper's desire for luxury at an exceptional value. While currently available in select stores and online, the company plans to roll out the full assortment to more doors in 2020. Stein Mart has also introduced a key item fine jewelry program in all stores. The key item assortment is composed of genuine diamond and sterling silver pieces priced under $200, all perfectly boxed for gifting. Stein Mart has partnered with Unique Designs, a New York based international fine jewelry manufacturer and wholesaler, for its fine jewelry needs.

07:35 EST Strongbridge Biopharma expects cash to fund operations through 2Q21 - The Company had $79.6M of cash and cash equivalents and no debt outstanding as of September 30, 2019; and the Company extended its cash runway guidance by at least three months, and now believes it can fund operations as currently planned through the second quarter of 2021.

07:32 EST Rafael Holdings says approved for listing on New York Stock Exchange - Rafael Holdings announced that it has been approved for listing on the New York Stock Exchange. The company anticipates that its Class B common stock will begin trading on the NYSE on November 21 with its current ticker symbol "RFL." The stock will continue trading on the NYSE American through the close of trading on November 20.

07:26 EST OPay raises $120M from investors in series B funding round - OPay announced that it raised $120M of series B funding, less than 6 months after it announced its last funding round of $50M in June. The company, which was incubated by Opera, is a mobile wallet and motorbike ridesharing provider, and is rapidly expanding. Series B investors included Meituan-Dianping, DragonBall Capital, GaoRong Capital, Source Code Capital, SoftBank Ventures Asia, Bertelsmann Asia Investments, Redpoint China, IDG Capital, Sequoia Capital China and GSR Ventures. The company plans to use the new capital to further accelerate its expansion across its multiple verticals, as well as entering new African markets. OPay launched its mobile payment service in August 2018, creating an infrastructure on which the company is now adding new services. Since its Series A funding, OPay tripled its active agents to over 140,000 and saw daily transaction volumes doubling to exceed $10M per day.

07:16 EST BiondVax says enrollment in Phase 3 trial of M-001 influenza vaccine complete - BiondVax announced that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal influenza vaccine candidate is complete.

07:11 EST Paramount Gold submits permit application for proposed Grassy Mountain project - Paramount Gold Nevada announced that Calico Resources USA Inc., Paramount's wholly owned subsidiary, has officially submitted its Consolidated Permit Application to the Oregon Department of Geology and Mineral Industries to enable the Company to build and operate its proposed, high grade underground gold mine located in Malheur County of eastern Oregon. The Application will be reviewed by the DOGAMI and cooperating agencies for completeness. Under Oregon law, the State has 90 days for the completeness review of the Application. When the Application is deemed complete, the State will issue a notice to proceed with the evaluation stage of the process. The State then has 225 days to review the Application, complete environmental and socioeconomic assessments, and issue draft permits. Following issuance of draft permits, DOGAMI has a maximum of 140 days to complete the public process and issue the final permits. Paramount has received final approval from the County of Malheur for all the required county permits including the key Conditional Use Permit. At the State level, Paramount has received acceptance for all 19 of the baseline data reports that it submitted. As reported in June, Paramount has initiated a NI 43-101 Feasibility Study for the Grassy Mountain Project. The Feasibility Study is being led by Ausenco Engineering Canada Inc. with expected completion in mid-2020. The permits and the Feasibility Study will provide the basis for Paramount to secure project financing for mine construction and operation.

07:08 EST Addus HomeCare provides update on operations in Illinois markets - Addus HomeCare provided an update on the federal Centers for Medicare and Medicaid Services approval of the State of Illinois budgeted rate increases and its expected impact on the company's operations in its Illinois markets. On November 15, the State of Illinois received and announced official CMS approval for both rate increases, with the first increase to be effective on December 1, 2019, and the second increase to be effective on January 1, 2020. The State of Illinois previously had finalized its fiscal year 2020 budget with the inclusion of an appropriation to raise in-home care rates to offset the costs of previous minimum wage increases in Chicago and other areas of the state that were imposed beginning on July 1, 2018. These rates were originally set to be effective July 1, 2019, with in-home care rates to be initially increased by 10.9% to $20.28 from $18.29 to partially offset the costs of the minimum wage hikes and then further increased on January 1, 2020 by an additional 7.7% to $21.84, providing full funding for both the Chicago minimum wage increases and a statewide raise for all current in-home caregivers. While the State of Illinois had required managed Medicaid plans to honor these rates as scheduled, it needed to receive CMS approval in advance of implementing new rates in the state Medicaid program.

07:05 EST MySize announces one-for-fifteen reverse stock split - My Size announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that is scheduled to become effective after trading closes on November 18. Beginning on November 19, the company's common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 62844N 208. The company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "MYSZ." As previously disclosed, at the My Size Annual Meeting of Stockholders held on August 5, the company's stockholders approved a proposal authorizing the company's Board of Directors, among other things, to effect a reverse stock split at a ratio in the range of 1-for-2 and 1-for-30 in order to increase the per share price and bid price of the company's common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.

07:04 EST Gulfport Energy says chairman David Houston will not seek re-election - The Company announced that two of its Board members, Craig Groeschel and Scott E. Streller, will step down from the Board by year-end. Furthermore, the Chairman of the Board, David L. Houston, has decided not to seek re-election at the Company's next 2020 annual meeting. The Company has been working with a leading nationally recognized search firm to identify and evaluate new independent director candidates in an effort to ensure that shareholders are represented by fresh, diverse voices with strong expertise and qualifications.

07:03 EST Lithia Motors promotes Chris Holzshu to COO - Lithia Motors announced that Chris Holzshu, Executive Vice President, has been promoted to COO. This promotion is part of the organization's redesign to further accelerate Lithia's growth while also realizing the substantial earnings potential in its existing store base.

07:01 EST Alkermes to acquire Rodin Therapeutics -

06:57 EST McDermott awarded 'sizeable' technology, EBE contracts - McDermott announced it has been awarded a "sizeable" technology contract from Baltic Chemical Company and a "sizeable" Extended Basic Engineering, or EBE, contract from China National Chemical Engineering No. 7 Construction Company Limited, or CC7. The ethane cracking project is owned by Baltic Chemical Complex LLC, a subsidiary of RusGazDobycha. McDermott defines a sizeable contract as between $1M and $50M.

06:54 EST United Bankshares, Carolina Financial to merge in $1.1B transaction - United Bankshares (UBSI) and Carolina Financial (CARO) announced that they have entered into a definitive merger agreement. The combined organization will be approximately $25B in assets and will rank in the top 35 largest banks in the U.S. based on market capitalization. United will acquire 100% of the outstanding shares of Carolina Financial in exchange for common shares of United. The exchange ratio will be fixed at 1.13 of United's shares for each share of Carolina Financial, resulting in an aggregate transaction value of approximately $1.1B. The merger agreement has been unanimously approved by the boards of directors of both companies. The merger is expected to close in the second quarter of 2020, subject to satisfaction of customary closing conditions, including receipt of customary regulatory approvals and approval by the stockholders of both companies. Carolina Financial will merge into United, and CresCom will merge into United Bank, with United and United Bank being the surviving entities. Carolina Financial's pending acquisition of North Carolina-based Carolina Trust BancShares (CART) is expected to close prior to year-end 2019.

06:51 EST SunExpress exercises option to purchase 10 additional Boeing 737 Max 8 jets - SunExpress and Boeing announced that SunExpress is exercising options for 10 additional Boeing 737 Max 8 airplanes to continue renewing its fleet. The purchase, valued at $1.2B according to list prices, adds to a previous SunExpress order for 32 Max airplanes. The 737 Max 8 is part of a family of airplanes that offer 130 to 230 seats and the ability to fly up to 3,850 nautical miles.

06:50 EST Cott Corp. to acquire The Water Guy, terms not disclosed - Cott Corporation announced that DS Services of America, a wholly-owned subsidiary of Cott, acquired substantially all of the assets of WG America Company and certain affiliated companies (The Water Guy). "The acquisition of The Water Guy, a provider of water solutions and office coffee service to residential and commercial customers, will grow the customer base of DS Services by more than 7,500 in eastern and central Pennsylvania, northern Maryland, Delaware and New Jersey. The Water Guy has become one of the largest independent distributors in the mid-Atlantic since its founding in 1990, growing its footprint and loyal customer base through organic growth and acquisitions."

06:45 EST Estee Lauder to acquire Dr. Jart+

06:41 EST HollyFrontier to construct new RDU at its Artesia refinery - HollyFrontier plans to construct a new RDU at its Artesia refinery. The RDU will have a production capacity of approximately 125M gallons a year and allow HollyFrontier to process soybean oil and other renewable feedstocks into renewable diesel. This investment will provide HollyFrontier the opportunity to meet the demand for low-carbon fuels while covering the cost of our annual RIN purchase obligation under current market conditions. The RDU, along with corresponding rail infrastructure and storage tanks, is estimated to have a total capital cost of $350M, and is expected to be completed in the first quarter of 2022. The RDU will be funded with cash on hand and is expected to generate an internal rate of return between 20%-30%.

06:38 EST Avalara names Jay Lee as Chief Marketing Officer - Avalara (AVLR) announced the appointment of marketing veteran Jay Lee as its new chief marketing officer. Lee brings more than two decades of marketing and business management experience to Avalara. He has overseen B2B strategic marketing and business development teams at some of the world's most recognizable companies including GE (GE) and American Express (AXP), and comes to Avalara from PayPal (PYPL), where he served as the global head of marketing for the company's Business Financing Solutions division.

06:36 EST Surface Oncology files IND for CD39 targeted antibody candidate, SRF617 - Surface Oncology announced that it has submitted an Investigational New Drug application to the U.S. FDA to support the initiation of a phase 1/1b clinical study of SRF617. At an inaugural R&D day, the company will share progress across its portfolio including clinical development plans for SRF617 and SRF388, and preclinical data supporting its new development candidate, SRF813, which targets the recently identified checkpoint protein CD112R to promote natural killer and T cell activation.

06:33 EST Aerie Pharmaceuticals to acquire Avizorex Pharma, S.L. in all-cash deal - Aerie Pharmaceuticals announced the signing of an agreement for the acquisition of Avizorex Pharma, S.L., a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The active ingredient in AVX-012 is a potent and selective agonist of the TRPM8 ion channel, a cold sensor and osmolarity sensor that regulates ocular surface wetness and blink rate. By stimulating these processes in a physiological manner, TRPM8 agonists have the potential to restore tear film stability and reduce discomfort in patients with dry eye. Positive results from the Phase 2a study support the therapeutic potential of AVX-012 to treat signs and symptoms of dry eye and Aerie is planning to initiate a larger Phase 2b study in late 2020. Under the terms of the Agreement, Aerie will acquire AVX Pharma in an all-cash transaction. Aerie will make an upfront payment of $10M, subject to customary adjustments, and AVX Pharma shareholders will be eligible to receive additional payments subject to achievement of certain clinical and regulatory performance milestones, plus royalties on net sales of approved products from AVX Pharma's development pipeline. In addition to AVX-012, Aerie will also be acquiring rights to other compounds targeting TRPM8. The parties expect to close the acquisition before the end of the year pending the completion of certain pre-closing obligations.

06:30 EST Aerie Pharmaceuticals to acquire Avizorex Pharma, S.L. in all cash deal

06:13 EST Cnooc appoints Wang Dongjin as chairman - Cnooc announced Wang Dongjin, an existing non-executive director of the company, has been appointed as chairman and chairman of the nomination committee of the company with effect from November 18. Wang no longer serves as vice chairman of the board.

06:12 EST Volkswagen confirms outlook for 2019 - The automaker previously forecast FY19 sales revenue to be up by up to 5% y/y.

06:08 EST Dicerna, Novo Nordisk enter pact to develop RNAi therapies - Dicerna Pharmaceuticals (DRNA) and Novo Nordisk (NVO) announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna's proprietary GalXC RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis, type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development. The agreement represents a significant investment by Novo Nordisk to secure access to Dicerna's proprietary GalXC RNAi platform, which complements its existing technology base. The collaboration provides Novo Nordisk with the capability to inhibit hepatocyte targets involved in disease regulation and has the potential to generate a number of clinical development candidates. The agreement enables each company to co-develop and co-commercialize product candidates discovered under the collaboration. Novo Nordisk will lead programs targeting cardio-metabolic disorders and other indications with Dicerna having the option to opt into two programs during clinical development. Dicerna retains rights to initiate two new orphan liver disease programs for which Novo Nordisk can opt in. For all co-development programs, the companies will share in the profit/loss of net sales of products consistent with each company's contribution to co-development costs. Under the terms of the agreement, Dicerna will receive: An upfront payment of $175M; A $50M equity investment in Dicerna at a premium; $25M annually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets; Up to $357.5M per target in development, regulatory, and commercialization milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

06:02 EST Karuna Therapeutics: KarXT met primary endpoint in Phase 2 trial - Karuna Therapeutics announced results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. In the clinical trial, KarXT demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale score compared to placebo and also demonstrated good overall tolerability. A statistically significant reduction in the secondary endpoints of PANSS-Positive and PANSS-Negative scores were also observed. KarXT was well tolerated in the Phase 2 trial, with similar discontinuation rates between KarXT (20%) and placebo (21%). The number of discontinuations due to treatment emergent adverse events were equal in the KarXT and placebo arms. In the clinical trial, patients demonstrated a clinically meaningful and statistically significant 11.6 point mean reduction over placebo in total PANSS score, the trial's primary efficacy endpoint. The magnitude of the improvement with KarXT compares favorably to meta-analyses of published clinicals trials of currently approved antipsychotic medicines which reported an average difference of nine to ten points in PANSS score versus placebo. Historically, changes as small as five points have supported the approval of current antipsychotics.

05:49 EST Boeing, Embraer announce JV to develop new markets for C-390 Millennium - Boeing (BA) and Embraer (ERJ) announced their joint venture to promote and develop new markets for the C-390 Millennium multi-mission airlift and air mobility aircraft will be called Boeing Embraer - Defense. The organization will only be operational after the companies' joint venture receives regulatory approvals and meets closing conditions. Embraer will have 51% ownership of Boeing Embraer - Defense, with Boeing holding the remaining 49%.

05:37 EST Yandex announces $300M share repurchase program - Yandex announces that its board has authorized a repurchase of up to $300M worth of Class A shares of Yandex N.V. Such shares may be repurchased from time to time in open market transactions. The repurchase program will be in effect for up to twelve months.

05:16 EST NIO Inc. appoints Wei Feng as CFO - NIO Inc. announced that Mr. Wei Feng is joining the company as its new CFO, effective November 18. Feng served as managing director and head of the auto and auto parts research team at China International Capital.